iTeos Therapeutics的动态

Come and see our latest news on #RadioDARPin therapeutics at #SNMMI

Cardiff Oncology presented five posters at the American Association for Cancer Research 2024 annual meeting, highlighting the significant potential of our lead molecule onvansertib. The five abstracts include the clinical results of a phase 1b/2 trial in KRAS-mutated metastatic #colorectalcancer (mCRC), the discovery of a novel mechanism for ovansertib, strong activity in preclinical models of ovarian and #smallcell lung cancer, and lastly the trial design of our ongoing phase 2 #clinicaltrial in first-line RAS-mutated mCRC, which is actively enrolling patients. ? For more information about the key highlights from the poster presentation, visit https://bit.ly/3TOH9ZB. ? The abstracts are available on the #AACR24 Online Program and are posted to the "Scientific Presentations" section of the Cardiff Oncology website. ? #Cancerresearch

Many thanks to?Daniel Levine for featuring Nuvalent, Inc. on The Bio Report podcast! I had a great time discussing the impact of kinase inhibitors on the precision oncology landscape,?the complex chemical challenges facing next generation kinase inhibitors, and Nuvalent, Inc.'s work towards our goal of solving for these challenges by leveraging?physician collaboration and?structure-based drug?design. #NSCLC #PrecisionOncology #Biotech #DrugDevelopment

Opna Bio's Bernice Matusow, MS, presented research yesterday at the American Association of Cancer Research annual meeting on OPN-6602, an EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical models of multiple myeloma. OPN-6602 significantly reduced tumor growth as a single agent (71% tumor growth inhibition) in the OPM-2 human multiple myeloma cell xenograft model as well as increased anti-tumor activity (>100% TGI) in combination studies. Opna plans to initiate a Phase 1 clinical study with OPN-6602 in multiple myeloma patients later this summer. #AACR#multiplemyeloma#Phase1

I am thrilled to share our recent publication entitled "Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay" in Medical Oncology Journal, Q2 Thanks for the whole team https://lnkd.in/dYRBB_zF

Are you attending #EANO2024? Meet Austin Smith and CAROL ANDREA PREGONERO GAMEZ, PhD at the 19th Meeting of the EANO European Association of Neuro-Oncology! ?? Austin and Carol will be in Glasgow, UK, from 17-20 October for the congress which aims to bridge gaps in the sector's understanding and management of central nervous system tumours. ?? Get in touch to arrange a meeting with the team to find out more about Ariceum's novel iodine radiolabelled PARP inhibitor #ATT001, which is in clinical development in patients with recurrent #glioblastoma in a first-in-human Phase 1 trial, CITADEL-123. #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide #oncology #cancer #EANO

This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R.

In our study, Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors, we explored how radiomics can be used to identify which patients are more likely to benefit from immunotherapy based on early follow-up scans. Meet business developer, Ysaline Leman, next week at the Immuno-Oncology Summit from April 23-24th in London, to explore the uses of radiomics in immunotherapy from dose response evaluation, to response prediction, to the correlation of radiomic features to tumour biology and much more. Can’t make it to London? Check out our blog post “From Images to Impact,” to delve into how radiomics is changing the paradigm of drug development in immunotherapy https://lnkd.in/edTi6qhD

Curious about the impact of high sensitivity and absolute quantification in liquid biopsy analysis? Listen to experts, including Prof. dr. Geert Martens from AZ Delta, as they unravel the significance of these aspects in liquid biopsy with Plasma-SeqSensei. NGS liquid-biopsy technology allows to detect DNA mutations?? like ESR1, PIK3CA and AKT1. This contributes to the development of therapeutics that enhance every phase of a patient’s journey and extend lives, especially breast cancer patients??. Learn more about Plasma-SeqSensei here: https://lnkd.in/eApzPmmb #SysmexBNL#LiquidBiopsy#PrecisionMedicine#ESR1#Breastcancer

More precision for better decision